News-Medical.Net on MSN2d
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIVGilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Despite recent negativity, several stocks, including Verizon Communications, Gilead Sciences, and Alibaba, have shaken off ...
Zacks Investment Research on MSN6dOpinion
Buy Gilead Sciences (GILD) Stock at 52-Week Highs?Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply ...
A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...
Zacks Investment Research on MSN1d
GILD Data on Once-Yearly Lenacapavir for HIV Prevention PositiveGilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.
In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks ...
Gilead presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Image credit: Shutterstock / Sundry Photography Gilead is set to launch a Phase III trial of its ...
Cosmopolitan India on MSN2d
7 books that every fierce feminist needs to readFrom Margaret Atwood's 'The Handmaid’s Tale' to 'Bad Feminist' by Roxane Gay, these books deserve a spot on every feminist's ...
Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a ...
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback